Year End Report 2013

Non-Regulatory

February 20, 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Full Year Report for 2013.

Financial Highlights

• Revenue for the 4th Quarter 2013 SEK 22.8 (14.3) million, and for the twelve month period 68.2 (49.2) million
• Operating result for the period amounted to SEK 1.7 (2.3) million, and for the twelve month period to 8.5 (7.3) million
• EBITDA for the period amounted to SEK 1.8 (2.4) million, and for the twelve month period to 8.8 (7.9) million
• Net result for the period amounted to SEK 0.9 (2.0) million, and for the twelve month period 6.6 (6.0)
• Cash and cash equivalents at the end of the period amounted to SEK 33.1 (21.2) million
• Cash flow for the period was SEK 12.5 (-4.6) million, and for the twelve month period 11.8 (8.6) million

Significant events during the fourth quarter

• Swedish Orphan Biovitrum (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, based on the Affibody® platform, into a phase I trial
• The COUNTERSTROKE consortium, which consists of six European research institutions and companies including Affibody, announced the initiation of a EU-funded research program for developing new therapeutics in the field of stroke. The consortium has received a six million euro grant from EU’s Seventh Framework Program (FP7-Health) to develop Affibody® molecules specific for HMGB1 for the treatment of stroke

Other significant events during 2013

• Dartmouth, LI-COR and Affibody received a US National Institutes of Health (NIH) grant for development and translation of fluorescence-guided surgery
• An Extraordinary General Meeting on August 20 approved a name change of the parent company from Affibody Holding to Affibody Medical as well as a consolidation of shares
• License agreement signed with Daewoong regarding the Albumod™ platform
• License agreement signed with Daiichi-Sankyo regarding the Albumod™ platform
• First patient included in breast and gastric cancer study with the substance ABY-025, which is part of the partnership with GE Healthcare on HER2-targeted imaging
• Affibody named winner of SwedenBIO Award 2013